Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
25 July 2014Website:
http://www.ocutx.comNext earnings report:
07 August 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Mon, 01 Jul 2024 21:48:21 GMTDividend
Analysts recommendations
Institutional Ownership
OCUL Latest News
Ocular Therapeutix is a biopharmaceutical company with a successful commercial product, Dextenza, generating $57.9 million in revenue in 2023. The company's main value driver is Axpaxli, an axitinib intravitreal implant in phase 3 trials for wet age-related macular degeneration (wet AMD). The company has a strong financial position with $482.9 million in cash and a 3.5-year cash runway, minimizing dilution risk.
The 2024 OIS Retina and ARVO conferences are taking place in Seattle, Washington.
Ocular Therapeutix (OCUL) is now considered oversold from a technical standpoint, suggesting that the intense selling pressure on the stock may be easing. Additionally, with Wall Street analysts largely raising their earnings estimates, there is a possibility of a turnaround in the stock's performance in the short term.
BEDFORD, Mass., March 26, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, “Ocular”, the “Company”), a biopharmaceutical company committed to enhancing people's vision and quality of life through the development and commercialization of innovative therapies for wet age-related macular degeneration (wet AMD), diabetic retinopathy, and other diseases and conditions of the eye, announced multiple scientific presentations at the 2024 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting being held April 5-8 in Boston, Massachusetts.
The consensus price target hints at a 34.7% upside potential for Ocular Therapeutix (OCUL). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Ocular Therapeutix (OCUL) came out with a quarterly loss of $0.28 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.24 per share a year ago.
BEDFORD, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, the “Company”), a biopharmaceutical company committed to enhancing people's vision and quality of life through the development and commercialization of innovative therapies for retinal disease and other diseases and conditions of the eye, today announced plans to report the Company's fourth quarter and full year 2023 financial results on Monday, March 11, 2024, after 4:00 p.m. Eastern Time.
Ocular Therapeutix (OCUL) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Does Ocular Therapeutix (OCUL) have what it takes to be a top stock pick for momentum investors? Let's find out.
Ocular Therapeutix (OCUL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 1(current)
What type of business is Ocular Therapeutix?
Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology. The company markets ReSure Sealant, an ophthalmic device to prevent wound leaks in corneal incisions following cataract surgery; and DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing OTX-TKI, an axitinib intravitreal implant that is in phase 1 clinical trials for the treatment of wet age-related macular degeneration and other retinal diseases; OTX-TIC, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the Company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC, as well as a discovery collaboration with Mosaic Biosciences to identify new targets and therapeutic agents for the treatment of dry age-related macular degeneration (dMAD). Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.
What sector is Ocular Therapeutix in?
Ocular Therapeutix is in the Healthcare sector
What industry is Ocular Therapeutix in?
Ocular Therapeutix is in the Biotechnology industry
What country is Ocular Therapeutix from?
Ocular Therapeutix is headquartered in United States
When did Ocular Therapeutix go public?
Ocular Therapeutix initial public offering (IPO) was on 25 July 2014
What is Ocular Therapeutix website?
https://www.ocutx.com
Is Ocular Therapeutix in the S&P 500?
No, Ocular Therapeutix is not included in the S&P 500 index
Is Ocular Therapeutix in the NASDAQ 100?
No, Ocular Therapeutix is not included in the NASDAQ 100 index
Is Ocular Therapeutix in the Dow Jones?
No, Ocular Therapeutix is not included in the Dow Jones index
When does Ocular Therapeutix report earnings?
The next expected earnings date for Ocular Therapeutix is 07 August 2024